Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hoth Therapeutics licenses UMB's RAMBAs to develop dermatology therapeutics

Executive Summary

Hoth Therapeutics Inc. gets exclusive rights within dermatology to develop and commercialize retinoic acid metabolism blocking agents (RAMBAs) from the University of Maryland, Baltimore (UMB) and its spin-out company Isoprene Pharmaceuticals Inc.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies